Cleveland BioLabs, Inc. (NASDAQ:CBLI) Sees Significant Decline in Short Interest

Cleveland BioLabs, Inc. (NASDAQ:CBLI) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totalling 47,700 shares, a drop of 31.9% from the December 15th total of 70,000 shares. Based on an average daily trading volume, of 42,500 shares, the short-interest ratio is currently 1.1 days. Currently, 1.0% of the shares of the stock are short sold.

Separately, ValuEngine lowered shares of Cleveland BioLabs from a “buy” rating to a “hold” rating in a research report on Friday, October 25th.

Shares of Cleveland BioLabs stock opened at $0.62 on Friday. Cleveland BioLabs has a fifty-two week low of $0.50 and a fifty-two week high of $2.16. The company’s 50 day moving average price is $0.69 and its two-hundred day moving average price is $1.05.

Cleveland BioLabs (NASDAQ:CBLI) last issued its earnings results on Thursday, November 14th. The biotechnology company reported ($0.04) earnings per share for the quarter. Cleveland BioLabs had a negative net margin of 241.79% and a negative return on equity of 93.20%. The company had revenue of $0.27 million during the quarter.

Cleveland BioLabs Company Profile

Cleveland BioLabs, Inc, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines.

Recommended Story: How is the discount rate different from the Federal Funds rate?

Receive News & Ratings for Cleveland BioLabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs and related companies with's FREE daily email newsletter.